Thirty-eight HCC patients with PVTT in whom other treatment modalities were not indicated underwent CRT. The total dose was translated into a biologic effective dose (BED) of 23.4–59.5 Gy10 (median 50.7 Gy10) as the α/β ratio = 10. Predictive factors including the age, performance status, Child–Pugh classification, PVTT size, and BED were evaluated for tumor response and survival.
Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were observed in 6 (15.8 % ), 11 (28.9 % ), 17 (44.7 % ), and 4 (10.5 % ) patients, respectively. The response rate (CR + PR) was 44.7 % . The PVTT size (<30 vs. 30 mm) and BED (<58 vs.
58 Gy10) were significant factors for tumor response. The median survival and 1-year survival rate were 9.6 months and 39.4 % . The Child–Pugh classification (A vs. B) and BED were significant factors for survival.
CRT is effective not only for tumor response but also for survival in HCC-PVTT patients in whom other treatment modalities are not indicated.